Lv7
4940 积分 2022-06-22 加入
Abstract 6528: Anti-PD-1 induces the endocytosis of the co-receptor from the surface of T-cells: Nivolumab is more effective than Pembrolizumab
21天前
已完结
Abstract 6528: Anti-PD-1 induces the endocytosis of the co-receptor from the surface of T-cells: Nivolumab is more effective than Pembrolizumab
29天前
已完结
Lenvatinib, toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: A biomolecular exploratory, phase II trial
1个月前
已完结
Graft PD-L1 as a predictive marker for rejection in PD-1 inhibitor therapy for recurrent liver tumors after transplant: A prospective pilot trial
2个月前
已完结
Graft PD-L1 as a predictive marker for rejection in PD-1 inhibitor therapy for recurrent liver tumors after transplant: A prospective pilot trial
2个月前
已关闭
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
7个月前
已完结
Comparison of efficacy between lenvatinib and bevacizumab in combination of immune checkpoint inhibitor and interventional triple therapy in Chinese advanced hepatocellular carcinoma – CLEAP 2302 study
7个月前
已完结
Abstract C069: Toripalimab an anti-PD-1 antibody that demonstrates potent T cell activation and enhanced clinical efficacy irrespective of PD-L1 status
8个月前
已关闭
Expert consensus on sequential surgery following conversion therapy based on combination of immune checkpoint inhibitors and antiangiogenic targeted drugs for advanced hepatocellular carcinoma (2024 edition)
9个月前
已完结
Efficacy and safety of tislelizumab combined with lenvatinib and FOLFOX4-HAIC in conversion therapy of middle-advanced stage hepatocellular carcinoma (HCC): A real-world retrospective study
9个月前
已完结
皖公网安备34019202002308
